Abstract

Background: The comorbidity of pain and depression is associated with high disease burden for patients in terms of disability, wellbeing, and use of medical care. Patients with major and minor depression often present themselves with pain to a general practitioner and recognition of depression in such cases is low, but evolving. Also, physical symptoms, including pain, in major depressive disorder, predict a poorer response to treatment. A multi-faceted, patient-tailored treatment programme, like collaborative care, is promising. However, treatment of chronic pain conditions in depressive patients has, so far, received limited attention in research. Cost effectiveness of an integrated approach of pain in depressed patients has not been studied. This article describes the aims and design of a study to evaluate effects and costs of collaborative care with the antidepressant duloxetine for patients with pain symptoms and a depressive disorder, compared to collaborative care with placebo and compared to duloxetine alone.

Additional Metadata
Keywords Depression, Pain, Duloxetine, Collaborative Care, Transmural, Primary Care
Persistent URL dx.doi.org/10.1186/1471-244X-13-147, hdl.handle.net/1765/50376
Journal BMC Psychiatry
Citation
de Heer, E, Dekker, J.J.M, van Eck van der Sluijs, J.F, Beekman, A.T.F, van Marwijk, H.W, Holwerda, T, … van der Feltz-Cornelis, C.M. (2013). Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled multi-Centre trial: TCC:PAINDIP. BMC Psychiatry, 13. doi:10.1186/1471-244X-13-147